Zacks Investment Research upgraded shares of Janux Therapeutics (NASDAQ:JANX – Get Rating) from a sell rating to a hold rating in a report released on Saturday, Zacks.com reports. According to Zacks, “Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, […]